Mirion (MIR) Q4 2025 earnings review
Nuclear Super Cycle Meets M&A Power
Mirion closed FY25 with record revenues and a swing to GAAP profitability, but the real story is the massive step-up for FY26. Powered by the 'nuclear renaissance' and the integration of Paragon Energy Solutions, management guides for 22-24% topline growth next year (vs 9% in Q4). While operational momentum is strong, the capital structure cleanup has come at a cost: Q4 Adjusted EPS fell 12% YoY despite double-digit EBITDA growth, driven by significant share dilution from convertible debt.
🐂 Bull Case
FY26 revenue guidance of 22-24% growth is a step-change from the single-digit run rate of FY25. This is driven by the Paragon acquisition and strong nuclear tailwinds, with organic growth projected at a healthy 5-7%.
Mirion has turned a corner on earnings quality. FY25 GAAP Net Income was $29.8M (vs a $36.6M loss in FY24), and Operating Cash Flow surged 45% YoY to $143.3M.
🐻 Bear Case
Despite Net Income rising, Q4 Adjusted EPS dropped to $0.15 (from $0.17) as the diluted share count swelled by ~63 million shares (+30% YoY), primarily due to convertible debt inclusion.
While the headline 23% growth is impressive, the 'Organic' engine is guiding for 5-7%, which is stable but not accelerating in line with the 'Nuclear Super Cycle' narrative. The growth is heavily purchased via M&A.
⚖️ Verdict: 🟢
Bullish. The Paragon acquisition perfectly times the nuclear capacity expansion cycle. The pivot to GAAP profitability and strong cash flow generation outweighs the near-term dilution pain.
Key Themes
The M&A Growth Wedge
The disparity between FY26 Total Revenue guidance (22-24%) and Organic Revenue guidance (5-7%) highlights the massive impact of the Paragon Energy Solutions and Certrec acquisitions. Mirion has successfully bought its way into a higher growth bracket, effectively adding ~17% growth through inorganic means.
Share Dilution Reality Check
Financial engineering has improved the debt profile but diluted equity holders. In Q4, Adjusted Net Income rose 12% to $40.1M, yet Adjusted EPS *fell* to $0.15 due to the diluted share count jumping from 212.8M to 275.6M. This includes ~30M shares linked to convertible debt.
Nuclear Power 'Super Cycle'
Orders exceeded $1 billion in 2025. Management cites growth across all three nuclear verticals: new utility-scale reactors, the installed base, and Small Modular Reactors (SMRs). The $150M contribution from the 'large opportunity pipeline' validates the long-term thesis.
Cash Flow Velocity
Operating Cash Flow accelerated significantly, reaching $143.3M in FY25 compared to $99.1M in FY24. This 45% jump indicates that the shift to GAAP profitability is backed by strong cash conversion, not just accounting adjustments.
Guidance Methodology Shift
A subtle but critical change in FY26 guidance: Adjusted EPS ($0.50-$0.57) now *includes* stock-based compensation (SBC). In FY25, SBC ($15.2M) was added back. This implies the 'real' comparable growth is stronger than the headline numbers suggest, as the new metric is burdened by an expense previously excluded.
Other KPIs
Stable/Accelerating. Improved from 27.4% in 24Q4 and 23.5% in 25Q3. The company is successfully passing through costs and realizing synergies, heading toward the long-term 30% target.
Reversing. A major milestone compared to the $36.6M loss in FY24 and $98.7M loss in FY23. The business has proven it can be profitable on a GAAP basis.
Increased significantly from $686M in FY24, primarily due to the addition of $754M in convertible debt. While this funded growth/refinancing, it introduced the dilution headwinds seen this quarter.
Guidance
Accelerating significantly vs FY25's 7.5%. Driven largely by the inclusion of Paragon Energy Solutions and Certrec acquisitions. Organic growth remains steady at 5-7%.
Accelerating. Implies substantial growth (+25-31%) over FY25's $228M. The implied margin of ~25.5% (midpoint) suggests continued operating leverage.
Accelerating. The midpoint represents a ~55% increase over the FY25 result (which landed around $106M based on previous guidance ranges). This confirms high cash conversion from the new acquisitions.
Stable growth. Compares to $0.46 in FY25. However, the quality of this earnings number is higher as it now *includes* stock-based compensation expense, whereas FY25 excluded it.
Key Questions
Organic Growth Disconnect
With the 'Nuclear Super Cycle' and record orders, why is FY26 organic revenue growth guided to only 5-7%, which is roughly flat vs FY25 performance?
SBC Methodology Change
Can you quantify the exact per-share impact of including Stock-Based Compensation in the FY26 Adjusted EPS guidance? What would the guidance be under the old methodology?
Medical Segment Visibility
The release heavily features Nuclear highlights. How did the Medical segment perform in Q4, particularly regarding the RTQA headwinds in China mentioned in previous quarters?